Live attenuated influenza vaccine (Fluenz ™): A guide to its use in the prevention of seasonal influenza in children in the EU

Pediatric Drugs

Volumn 14, Issue 4, 2012, Pages 271-279

  Scott, Lesley J ^a   Carter, Natalie J ^a   Curran, Monique P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Clinical Q and A; Children; Influenza virus infections; Influenza virus vaccine; Influenza virus vaccine live

Indexed keywords

CHICKENPOX VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; POLIOMYELITIS VACCINE; RUBELLA VACCINE;

ARTICLE; ASTHMA; CELLULAR IMMUNITY; CHILL; DECREASED APPETITE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EUROPEAN UNION; FATIGUE; FEVER; GASTROINTESTINAL INFECTION; HEADACHE; HERD IMMUNITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION; INFECTION PREVENTION; INFESTATION; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; IRRITABILITY; MYALGIA; NONHUMAN; NOSE CONGESTION; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; RHINITIS; RHINORRHEA; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEASONAL INFLUENZA; SEROCONVERSION; SIDE EFFECT; SORE THROAT; VACCINATION; VIRUS SHEDDING; VIRUS STRAIN; VIRUS TRANSMISSION; WHEEZING;

ADMINISTRATION, INTRANASAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; EUROPEAN UNION; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, ATTENUATED;

EID: 84862539256     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11207080-000000000-00000     Document Type: Article

References (35)

1. Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist- Fluenz-): A review of its use in the prevention of seasonal influenza in children and adults. Drugs 2011 71 (12): 1591-1622
2. Osterholm MT, Kelley NS, Sommer A, et al. Efficacy and effectiveness of influenza vaccines: A systematic review and meta-Analysis. Lancet Infect 2012 12 (1): 36-44
3. Global pandemic influenza action plan to increase vaccine supply: progress report 2008 (WHO/IVB/09/05). Geneva: World Health Organization, 2009
4. Block SL, Reisinger KS, Hultquist M, et al. Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjects. Antimicrob Agents Chemother 2007 Nov 51 (11): 4001-8
5. Fluenz- nasal spray suspension influenza vaccine (live attenuated, nasal): summary of product characteristics. London: European Medicines Agency, 2012 Feb 12
6. Flumist- influenza vaccine (live attenuated): intranasal spray: product monograph. Mississauga (ON): AstraZeneca Canada, 2011 Apr 12
7. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-Adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998 338 (20): 1405-1412
8. Bracco Neto H, Farhat CK, Tregnaghi MW, et al. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J 2009 May 28 (5): 365-371
9. Tam JS, Capeding MRZ, Lum LCS, et al. Efficacy and safety of a live attenuated, cold-Adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 2007 Jul 26 (7): 619-628
10. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-Adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000 136 (2): 168-175
11. Bernstein DI, Yan L, Treanor J, et al. Effect of yearly vaccinations with live, attenuated, cold-Adapted, trivalent, intranasal influenza vaccines on antibody responses in children. Pediatr Infect Dis J 2003 Jan 22 (1): 28-34
12. Nolan T, Bernstein DI, Block SL, et al. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measlesmumps- rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics 2008 Mar 121 (3): 508-516
13. Breiman RF, Brooks WA, Goswami D, et al. A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children. Vaccine 2009 Sep 4 27 (40): 5472-9
14. Vesikari T, Karvonen A, Korhonen T, et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-Adapted influenza virus vaccine. Pediatr Infect Dis J 2006 Jul 25 (7): 590-595
15. Block SL, Yogev R, Hayden FG, et al. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine 2008 Sep 8 26 (38): 4940-6
16. Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, cold-Adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000 181 (3): 1133-7
17. Forrest BD, Pride MW, Dunning AJ, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008 Jul 15 (7): 1042-1053
18. He X-S, Holmes TH, Zhang C, et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006 Dec 80 (23): 11756-66
19. Sasaki S, Jaimes MC, Holmes TH, et al. Comparison of the influenza virusspecific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007 Jan 81 (1): 215-228
20. Vesikari T, Fleming DM, Aristegui JF, et al. Safety, efficacy, and effectiveness of cold-Adapted influenza vaccine-trivalent against community-Acquired, culture-confirmed influenza in young children attending day care. Pediatrics 2006 Dec 118 (6): 2298-2312
21. Belshe RB, Gruber WC. Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatr Infect Dis J 2000 May 19 (5 Suppl. 1): S66-71
22. Ambrose CS, Wu X, Knuf M, et al. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A recent meta-Analysis of 8 randomized controlled studies. Vaccine 2012 30 (5): 886-892
23. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007 Feb 15 356 (7): 685-696
24. Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006 Oct 25 (10): 870-879
25. Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-Adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006 Oct 25 (10): 860-869
26. Ambrose C, Levin M, Belshe R. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respi Viruses 2011 5 (2): 67-75
27. Lum LCS, Borja-Tabora CF, Breiman RF, et al. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine 2010 28: 1566-1574
28. Davis MM, King JC, Moag L, et al. Countywide school-based influenza immunization: direct and indirect impact on student absenteeism. Pediatrics 2008 Jul 122 (1): e260-5
29. Glezen WP, Gaglani MJ, Kozinetz CA, et al. Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. J Infect Dis 2010 Dec 1 202 (11): 1626-1633
30. King JC, Stoddard JJ, Gaglani MJ, et al. Effectiveness of school-based influenza vaccination. N Engl J Med 2006 Dec 355 (24): 2523-2532
31. Treanor JJ, Kotloff K, Betts RF, et al. Evaluation of trivalent, live, coldadapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 2000 18 (9-10): 899-906
32. Bergen R, Black S, Shinefield H, et al. Safety of cold-Adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 2004 Feb 23 (2): 138-144
33. FluMist intranasal live attenuated influenza vaccine, 2011-2012 formula: US prescribing information. Gaithersburg (MD): MedImmune, 2011 May
34. Ambrose CS, Yi T, Falloon J. An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years. Influenza Other Respi Viruses 2011 Nov 5 (6): 389-397
35. Belshe RB, Ambrose CS, Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 2008 26 Suppl. 4 D10-6